KemPharm Company Profile (NASDAQ:KMPH)

About KemPharm (NASDAQ:KMPH)

KemPharm logoKemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company's product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP). The Company is developing KP201/APAP as an immediate release (IR), a product candidate for the short-term, or no longer than 14 days for the management of acute pain. The Company has designed KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. The Company also focuses on developing the pipeline of additional prodrug product candidates that targets pain and attention deficit hyperactivity disorder (ADHD). The Company's products include KP201/IR (APAP-free), KP511/ER, KP415, KP606/IR and KP746.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:KMPH
  • CUSIP: N/A
  • Web: www.kempharm.com
Capitalization:
  • Market Cap: $61.51 million
  • Outstanding Shares: 14,646,000
Average Prices:
  • 50 Day Moving Avg: $4.26
  • 200 Day Moving Avg: $3.91
  • 52 Week Range: $2.90 - $7.84
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.69
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: ($2.04) per share
  • Price / Book: -2.06
Profitability:
  • EBIDTA: ($34,690,000.00)
  • Return on Assets: -17.21%
Debt:
  • Debt-to-Equity Ratio: -9.26%
  • Current Ratio: 11.45%
  • Quick Ratio: 11.45%
Misc:
  • Average Volume: 32,326 shs.
  • Beta: -1.46
  • Short Ratio: 13.7
 

Frequently Asked Questions for KemPharm (NASDAQ:KMPH)

What is KemPharm's stock symbol?

KemPharm trades on the NASDAQ under the ticker symbol "KMPH."

How were KemPharm's earnings last quarter?

KemPharm Inc (NASDAQ:KMPH) issued its earnings results on Wednesday, May, 10th. The company reported ($0.84) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by $0.21. View KemPharm's Earnings History.

Where is KemPharm's stock going? Where will KemPharm's stock price be in 2017?

3 brokers have issued 1 year target prices for KemPharm's stock. Their forecasts range from $7.00 to $13.00. On average, they anticipate KemPharm's share price to reach $9.33 in the next twelve months. View Analyst Ratings for KemPharm.

Who are some of KemPharm's key competitors?

When did KemPharm IPO?

(KMPH) raised $60 million in an IPO on Thursday, April 16th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers.

Who owns KemPharm stock?

KemPharm's stock is owned by many different of institutional and retail investors. Top institutional investors include Arete Wealth Advisors LLC (5.81%), Creative Planning (3.10%), Vanguard Group Inc. (2.05%), C WorldWide Group Holding A S (1.24%), Victory Capital Management Inc. (0.90%) and Parkwood LLC (0.86%). Company insiders that own KemPharm stock include Daniel L Cohen, David S Tierney, R Laduane Clifton and Travis C Mickle. View Institutional Ownership Trends for KemPharm.

Who sold KemPharm stock? Who is selling KemPharm stock?

KemPharm's stock was sold by a variety of institutional investors in the last quarter, including Menta Capital LLC. View Insider Buying and Selling for KemPharm.

Who bought KemPharm stock? Who is buying KemPharm stock?

KemPharm's stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Morgan Stanley, C WorldWide Group Holding A S, Creative Planning, Bank of New York Mellon Corp, Arete Wealth Advisors LLC, Vanguard Group Inc. and Geode Capital Management LLC. Company insiders that have bought KemPharm stock in the last two years include Daniel L Cohen, David S Tierney, R Laduane Clifton and Travis C Mickle. View Insider Buying and Selling for KemPharm.

How do I buy KemPharm stock?

Shares of KemPharm can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of KemPharm stock cost?

One share of KemPharm stock can currently be purchased for approximately $4.20.

Analyst Ratings

Consensus Ratings for KemPharm (NASDAQ:KMPH) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.33 (122.22% upside)

Analysts' Ratings History for KemPharm (NASDAQ:KMPH)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017Royal Bank of CanadaReiterated RatingBuy$8.00MediumView Rating Details
5/10/2017Oppenheimer Holdings Inc.Set Price TargetBuy$13.00LowView Rating Details
3/12/2017Canaccord GenuitySet Price TargetBuy$7.00HighView Rating Details
8/15/2015Cowen and CompanyReiterated RatingBuyN/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for KemPharm (NASDAQ:KMPH)
Earnings by Quarter for KemPharm (NASDAQ:KMPH)
Earnings History by Quarter for KemPharm (NASDAQ:KMPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.63)($0.84)ViewN/AView Earnings Details
3/9/2017Q4 2016($0.70)($0.68)ViewListenView Earnings Details
11/9/2016Q3 2016($0.70)($0.92)ViewListenView Earnings Details
8/10/2016Q2($0.94)($0.58)ViewListenView Earnings Details
5/12/2016Q1($0.56)($0.20)ViewListenView Earnings Details
3/10/2016Q4($0.50)($0.64)ViewListenView Earnings Details
11/12/2015Q315($0.48)($0.68)ViewListenView Earnings Details
8/13/2015Q215($0.47)($0.59)ViewListenView Earnings Details
5/27/2015Q1($0.49)($2.50)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for KemPharm (NASDAQ:KMPH)
2017 EPS Consensus Estimate: ($2.78)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.69)($0.69)($0.69)
Q2 20171($0.63)($0.63)($0.63)
Q3 20171($0.66)($0.66)($0.66)
Q4 20171($0.80)($0.80)($0.80)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for KemPharm (NASDAQ:KMPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for KemPharm (NASDAQ:KMPH)
Insider Ownership Percentage: 22.80%
Institutional Ownership Percentage: 44.36%
Insider Trades by Quarter for KemPharm (NASDAQ:KMPH)
Institutional Ownership by Quarter for KemPharm (NASDAQ:KMPH)
Insider Trades by Quarter for KemPharm (NASDAQ:KMPH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/31/2017Daniel L CohenEVPBuy2,500$4.48$11,200.00View SEC Filing  
3/24/2017R. Laduane CliftonCFOBuy1,000$4.24$4,240.00View SEC Filing  
3/22/2017Travis C MickleCEOBuy2,000$4.10$8,200.00View SEC Filing  
3/20/2017David S TierneyDirectorBuy1,000$4.20$4,200.00View SEC Filing  
11/30/2016Daniel L CohenEVPBuy5,000$3.50$17,500.00View SEC Filing  
9/6/2016Daniel L CohenEVPBuy10,000$4.75$47,500.00View SEC Filing  
8/17/2016Travis C MickleCEOBuy5,000$4.95$24,750.00View SEC Filing  
3/29/2016Travis C MickleCEOBuy2,450$14.57$35,696.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for KemPharm (NASDAQ:KMPH)
Latest Headlines for KemPharm (NASDAQ:KMPH)
Source:
DateHeadline
americanbankingnews.com logoQ2 2017 EPS Estimates for KemPharm Inc Reduced by Oppenheimer Holdings (KMPH)
www.americanbankingnews.com - May 15 at 7:46 AM
americanbankingnews.com logoFY2021 EPS Estimates for KemPharm Inc (KMPH) Cut by Analyst
www.americanbankingnews.com - May 12 at 6:56 PM
americanbankingnews.com logoKemPharm Inc (KMPH) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 11 at 7:36 PM
americanbankingnews.com logoKemPharm Inc (KMPH) Given a $13.00 Price Target by Oppenheimer Holdings Inc. Analysts
www.americanbankingnews.com - May 11 at 2:56 PM
cnbc.com logoKemPharma reports 1Q loss
www.cnbc.com - May 10 at 6:06 PM
finance.yahoo.com logoKemPharm, Inc. Reports First Quarter 2017 Results
finance.yahoo.com - May 10 at 6:06 PM
finance.yahoo.com logoInvestor Network: KemPharm, Inc. to Host Earnings Call
finance.yahoo.com - May 10 at 1:04 PM
americanbankingnews.com logoKemPharm Inc (KMPH) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - May 5 at 12:46 AM
americanbankingnews.com logoKemPharm (KMPH) Receiving Somewhat Favorable Press Coverage, Report Finds
www.americanbankingnews.com - May 4 at 2:18 PM
americanbankingnews.com logoKemPharm Inc (KMPH) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 4 at 1:17 AM
americanbankingnews.com logoZacks Investment Research Downgrades KemPharm Inc (KMPH) to Hold
www.americanbankingnews.com - May 4 at 1:16 AM
americanbankingnews.com logoKemPharm (KMPH) Getting Somewhat Negative Press Coverage, Study Finds
www.americanbankingnews.com - May 1 at 3:42 PM
finance.yahoo.com logoKemPharm, Inc. to Report First Quarter 2017 Results
finance.yahoo.com - May 1 at 1:00 PM
americanbankingnews.com logoZacks: Analysts Expect KemPharm Inc (KMPH) to Announce -$0.61 Earnings Per Share
www.americanbankingnews.com - April 27 at 11:20 PM
americanbankingnews.com logoKemPharm (KMPH) Receives News Sentiment Rating of 0.31
www.americanbankingnews.com - April 20 at 11:49 PM
americanbankingnews.com logoKemPharm (KMPH) Earns News Impact Score of 0.31
www.americanbankingnews.com - April 17 at 9:10 AM
americanbankingnews.com logoKemPharm Inc (KMPH) Given a $8.00 Price Target at Royal Bank of Canada
www.americanbankingnews.com - April 13 at 6:14 PM
americanbankingnews.com logoKemPharm (KMPH) Earning Favorable News Coverage, Study Finds
www.americanbankingnews.com - April 13 at 3:18 PM
americanbankingnews.com logoKemPharm Inc (KMPH) Expected to Post Quarterly Sales of $0.00
www.americanbankingnews.com - April 8 at 9:07 AM
americanbankingnews.com logo-$0.61 EPS Expected for KemPharm Inc (KMPH) This Quarter
www.americanbankingnews.com - April 6 at 6:18 PM
americanbankingnews.com logo Brokerages Set $27.33 Target Price for KemPharm Inc (KMPH)
www.americanbankingnews.com - April 4 at 12:43 AM
americanbankingnews.com logoZacks Investment Research Upgrades KemPharm Inc (KMPH) to "Hold"
www.americanbankingnews.com - April 2 at 9:55 AM
biz.yahoo.com logoKEMPHARM, INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
biz.yahoo.com - March 28 at 5:46 PM
finance.yahoo.com logoKemPharm to Present at the 2nd Annual Neuroscience Biopartnering and Investment Forum
finance.yahoo.com - March 27 at 10:43 AM
americanbankingnews.com logoKemPharm Inc (KMPH) Stock Rating Reaffirmed by Oppenheimer Holdings Inc.
www.americanbankingnews.com - March 24 at 11:04 PM
us.rd.yahoo.com logoKemPharm Presents Clinical Data for Opioid Prodrug Candidates at American Academy of Pain Medicine’s Annual Meeting
us.rd.yahoo.com - March 16 at 6:58 PM
us.rd.yahoo.com logo7:32 am KemPharm presents data on KP511 and KP201/IR at the American Academy of Pain Medicine Annual Meeting
us.rd.yahoo.com - March 16 at 6:58 PM
finance.yahoo.com logoKEMPHARM, INC Financials
finance.yahoo.com - March 16 at 6:58 PM
finance.yahoo.com logoCan The Uptrend Continue for KemPharm (KMPH)?
finance.yahoo.com - March 15 at 6:27 PM
americanbankingnews.com logoKemPharm Inc (KMPH) Upgraded by Zacks Investment Research to “Buy”
www.americanbankingnews.com - March 15 at 12:24 AM
americanbankingnews.com logoOppenheimer Holdings Comments on KemPharm Inc’s FY2021 Earnings (KMPH)
www.americanbankingnews.com - March 13 at 2:48 PM
biz.yahoo.com logoKEMPHARM, INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 10 at 7:23 PM
globenewswire.com logoKemPharm, Inc. Reports Fourth Quarter and Year End 2016 Results - GlobeNewswire (press release)
globenewswire.com - March 10 at 7:57 AM
us.rd.yahoo.com logoKemPharm, Inc. Reports Fourth Quarter and Year End 2016 Results
us.rd.yahoo.com - March 9 at 9:06 PM
biz.yahoo.com logoQ4 2016 KemPharm Inc Earnings Release - After Market Close
biz.yahoo.com - March 9 at 8:48 AM
americanbankingnews.com logoKemPharm Inc (KMPH) Set to Announce Earnings on Thursday
www.americanbankingnews.com - March 8 at 9:19 AM
finance.yahoo.com logoKemPharm, Inc. to Report Fourth Quarter and Year End 2016 Results
finance.yahoo.com - February 28 at 9:37 AM
finance.yahoo.com logo7:31 am KemPharm announces issuance of two new patents by the USPTO, one related to the KP511 family of compounds and another related to KP201
finance.yahoo.com - February 23 at 6:09 PM
biz.yahoo.com logoKEMPHARM, INC Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - February 16 at 5:50 PM
finance.yahoo.com logoKemPharm to Present at Upcoming Investor Conferences
finance.yahoo.com - February 7 at 7:27 PM
businesswire.com logoSHAREHOLDER ALERT: Goldberg Law PC Announces an ... - Business Wire (press release)
www.businesswire.com - February 4 at 4:53 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of KemPharm, Inc. and Advises Investors with Losses to Contact the Firm
finance.yahoo.com - February 3 at 11:52 PM
businesswire.com logoCRITICAL INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of KemPharm, Inc. and Encourages ... - Business Wire (press release)
www.businesswire.com - January 27 at 8:19 PM
finance.yahoo.com logoCRITICAL INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of KemPharm, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - January 27 at 8:19 PM
prnewswire.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims ... - PR Newswire (press release)
www.prnewswire.com - January 23 at 6:29 PM
prnewswire.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC ... - PR Newswire (press release)
www.prnewswire.com - January 23 at 6:29 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of KemPharm, Inc. (KMPH)
finance.yahoo.com - January 23 at 6:29 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of KemPharm, Inc. - KMPH
finance.yahoo.com - January 23 at 6:29 PM
finance.yahoo.com logoShareholder Alert: Lundin Law PC Announces an Investigation of KemPharm, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - January 23 at 6:29 PM
prnewswire.com logoKEMPHARM NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Significant Losses Investing In ... - PR Newswire (press release)
www.prnewswire.com - January 21 at 5:58 PM

Social

Chart

KemPharm (KMPH) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff